Sagent Pharmaceuticals

Dear Payer/Insurer Colleagues:

The biosimilar world continues to evolve, with a growing number of biosimilars primed for approval and launch throughout 2019. As the treatment landscape for biologics strives to take advantage of the potential savings of these agents, providers continue to look to their partners in the payer and insurer communities for guidance and support in fully adopting these biosimilar options.

Sagent Pharmaceuticals wants to aid you in upholding your responsibility to clinicians and patients by providing key information on biosimilars, and in particular the important role that interchangeable biosimilars promise to play in increasing access and reducing cost to these crucial therapies.

Please visit to learn more about the biosimilar approval process, interchangeability, and the value prospects of the interchangeable biosimilars.

© Copyright 2019 Sagent Pharmaceuticals
1901 N. Roselle Road, Suite 450
Schaumburg, IL 60195 USA


This email was sent on behalf of SAGENT by HealthEconomics.Com, 449 S. Mill View Way, Ponte Vedra Beach, FL 32082.
If you don't wish to receive further Industry Leaders News Updates from us, you may immediately unsubscribe from this list here, or send your request in writing to the address above. Read more about our privacy policy here. You may also request a copy in writing using the address above.